Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Harrow Health, Inc.NASDAQ: HROW

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $3.84M fell 15.8% year over year, ahead of the -34.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.

Context

  • Stock-based compensation amounted to 4.6% of revenue in FY2025, down 4.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -15.8% holds above the trailing-twelve-month pace of -34.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.84M+1.0% QoQ
Last fiscal yearDec 2025
$12.5M-29.0% YoY
LTMMar 2026
$11.78M-34.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.8%——
1 year-29.0%——
3-year CAGR+16.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.5M USD
Year-over-year change
-29.0%
4-year CAGR
+21.5%

Stock-Based Compensation vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.6% is the 7th highest of 8, against a peer median of +17.9%.
  • Stock-based compensation amounts to 4.4% of revenue for HROW, versus a peer median of 254.5%.
HROW Competitors
Stock-Based Compensation for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$72M USD-33.9%+33.9%1.4%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$66.79M USD+91.9%+45.8%9.8%
KODKodiak Sciences Inc.LTM Sep 2026$63.89M USD+17.9%-17.8%—
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M USD+35.8%+36.5%92.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M USD-0.5%+25.3%416.2%
OCSOculis Holding AGLTM Mar 2026CHF 18.42M CHF+63.4%+171.2%3653.8%
HROWHarrow Health, Inc.LTM Mar 2026$11.78M USD-34.6%+16.2%4.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M USD-37.3%+4.9%1543.3%
TTRXTurn Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding HROW) —+17.9%+33.9%254.5%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Depreciation & Amortization2.4M3.67M12.34M14.54M19.68M
Deferred Income Tax00000
Stock-Based Compensation5.75M7.97M15.7M17.62M12.5M
Change in Working Capital(253K)(5.57M)(7.14M)(44.63M)185K
Accounts Receivables(1.83M)(1.86M)(30.34M)(80.23M)5.01M
Inventory(255K)(2.32M)(4.33M)165K(2.82M)
Accounts Payables1.73M933K31.8M37.5M(4.61M)
Other Working Capital103K(2.32M)(4.26M)(2.06M)2.6M
Other Non-Cash Items15.2M9.72M7.35M7.75M16.64M
Operating Cash Flow5.08M1.71M3.84M(22.2M)43.86M
Capital Expenditures(28.51M)(7.77M)(152.55M)(38.67M)(1.1M)
Acquisitions (Net)9.83M000(4.36M)
Purchases of Investments00000
Sales of Investments9.83M005.51M0
Other Investing Activities(36.55M)854K(151.09M)(37.08M)(215K)
Investing Cash Flow(18.69M)(1.74M)(152.55M)(33.16M)(5.46M)
Debt Repayment71.07M31.72M74.64M29.78M11.84M
Common Stock Issued022.66M64.52M0467K
Common Stock Repurchased00000
Dividends Paid(127K)0000
Other Financing Activities(19.12M)(234K)(12.63M)(1.25M)(25.04M)
Financing Cash Flow51.47M54.14M126.53M28.53M(12.72M)
Effect of Forex Changes00000
Net Change in Cash37.87M54.1M(22.19M)(26.84M)25.68M
Free Cash Flow(23.43M)(6.07M)(148.71M)(60.88M)42.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.